SINOVAC BIOTECH LTD Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2010 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Sinovac Biotech Ltd quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2010 to Q4 2023.
  • Sinovac Biotech Ltd Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending December 31, 2023 was $440M, a 18.1% decline year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $440M -$97.1M -18.1% Dec 31, 2023 20-F 2024-04-29
Q4 2022 $537M -$415M -43.6% Dec 31, 2022 20-F 2024-04-29
Q4 2021 $952M +$699M +276% Dec 31, 2021 20-F 2023-05-01
Q4 2020 $253M +$140M +123% Dec 31, 2020 20-F 2022-04-29
Q4 2019 $114M +$39.3M +52.7% Dec 31, 2019 20-F 2021-04-22
Q4 2018 $74.5M +$8.26M +12.5% Dec 31, 2018 20-F 2020-04-30
Q4 2017 $66.2M +$16.4M +32.9% Dec 31, 2017 20-F 2019-04-29
Q4 2016 $49.8M +$10.8M +27.7% Dec 31, 2016 20-F 2018-05-11
Q4 2015 $39M -$1.7M -4.17% Dec 31, 2015 20-F 2017-11-22
Q4 2014 $40.7M +$8.79M +27.5% Dec 31, 2014 20-F 2016-04-25
Q4 2013 $31.9M +$8.49M +36.2% Dec 31, 2013 20-F 2015-04-29
Q4 2012 $23.4M +$5.61M +31.4% Dec 31, 2012 20-F 2014-04-16
Q4 2011 $17.8M -$4.54M -20.3% Dec 31, 2011 20-F/A 2013-05-23
Q4 2010 $22.4M Dec 31, 2010 20-F 2012-04-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.